Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Inhaled KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

Next Previous
Trial Profile

A Phase 1 Study of Inhaled KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KB 408 (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Adverse reactions; Proof of concept
  • Acronyms Serpentine-1
  • Sponsors Krystal Biotech

Most Recent Events

  • 06 May 2025 According to a Krystal Biotech media release, the company continues to enroll in Cohort 2 and is working to enroll in Cohort 3 of SERPENTINE-1. The Company expects to report molecular results for the additional Cohort 2 and 3 patients later this year.
  • 19 Feb 2025 According to a Krystal Biotech media release, company expects to report results from both cohorts in 2H 2025.
  • 12 Dec 2024 According to a Krystal Biotech media release, the Company will enroll two additional patients in Cohort 2 of SERPENTINE-1 and expects to provide additional data updates in 2025. In parallel, the Company will open Cohort 3 to explore safety and gene delivery at the highest dose of KB408.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top